Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalating Dose D-serine in Schizophrenia
NCT00322023Phase 2Completed
- Sponsor
- Nathan S. Kline Institute for Psychiatric Research
- Start
- Mar 2006
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of d-serine in schizophrenia (3 arms), sponsored by Nathan S. Kline Institute for Psychiatric Research. Primary endpoint: Renal Safety Measures at 4 weeks. Started Mar 2006; status: completed.
02
Drugs
d-serine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00322023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322023.